Literature DB >> 28844067

Cerebellar lobule atrophy and disability in progressive MS.

Sirio Cocozza1,2, Maria Petracca1,3, Enricomaria Mormina1,4, Korhan Buyukturkoglu1, Kornelius Podranski1, Monika M Heinig1, Giuseppe Pontillo2, Camilla Russo2, Enrico Tedeschi2, Cinzia Valeria Russo3, Teresa Costabile3, Roberta Lanzillo3, Asaff Harel1, Sylvia Klineova1, Aaron Miller1, Arturo Brunetti2, Vincenzo Brescia Morra3, Fred Lublin1, Matilde Inglese5,6,7.   

Abstract

OBJECTIVE: To investigate global and lobular cerebellar volumetries in patients with progressive multiple sclerosis (MS), testing the contribution of cerebellar lobular atrophy to both motor and cognitive performances.
METHODS: Eighty-two patients with progressive MS and 46 healthy controls (HC) were enrolled in this cross-sectional study. Clinical evaluation included motor and cognitive testing: Expanded Disability Status Scale, cerebellar Functional System score, Timed 25-Foot Walk Test, 9-Hole Peg Test (9-HPT), Symbol Digit Modalities Test (SDMT), Brief Visuospatial Memory Test-Revised (BVMT) and California Verbal Learning Test II (CVLT). Cerebellar volumes were automatically obtained using the Spatially Unbiased Infratentorial Toolbox. A hierarchical multiple linear regression analysis was performed to assess the relationship between MRI variables of supratentorial and cerebellar damage (grey matter fraction, T2 lesion volume, metrics of cerebellar atrophy and cerebellar lesion volume) and motor/cognitive scores.
RESULTS: Patients with MS exhibited lower cerebellar volumes compared with HC. Regression analysis showed that cerebellar metrics accounted for extra variance in both motor and cognitive performances, with cerebellar lesion volume, cerebellar Lobules VI, Crus I and VIIIa atrophy being independent predictors of 9-HPT, SDMT, BVMT and CVLT performances.
CONCLUSIONS: Atrophy of specific cerebellar lobules explains different aspects of motor and cognitive disability in patients with progressive MS. Investigation of cerebellar involvement provides further insight into the pathophysiological basis of clinical disability in progressive MS. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Mesh:

Year:  2017        PMID: 28844067     DOI: 10.1136/jnnp-2017-316448

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  17 in total

1.  An MRI evaluation of grey matter damage in African Americans with MS.

Authors:  Maria Petracca; Wafaa Zaaraoui; Sirio Cocozza; Roxana Vancea; Jonathan Howard; Monika M Heinig; Lazar Fleysher; Niels Oesingmann; Jean-Philippe Ranjeva; Matilde Inglese
Journal:  Mult Scler Relat Disord       Date:  2018-07-12       Impact factor: 4.339

2.  Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy?

Authors:  Sirio Cocozza; Giuseppe Pontillo; Camilla Russo; Cinzia Valeria Russo; Teresa Costabile; Alessio Pepe; Enrico Tedeschi; Roberta Lanzillo; Vincenzo Brescia Morra; Arturo Brunetti; Matilde Inglese; Maria Petracca
Journal:  J Neurol       Date:  2018-07-28       Impact factor: 4.849

3.  Cerebellar volume loss in radiologically isolated syndrome.

Authors:  Ilena C George; Mohamed Mounir El Mendili; Matilde Inglese; Christina J Azevedo; Orhun Kantarci; Christine Lebrun; Aksel Siva; Darin T Okuda; Daniel Pelletier
Journal:  Mult Scler       Date:  2019-11-04       Impact factor: 6.312

4.  Automatic cerebellum anatomical parcellation using U-Net with locally constrained optimization.

Authors:  Shuo Han; Aaron Carass; Yufan He; Jerry L Prince
Journal:  Neuroimage       Date:  2020-05-11       Impact factor: 6.556

5.  The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.

Authors:  Raffaello Bonacchi; Alessandro Meani; Elisabetta Pagani; Olga Marchesi; Massimo Filippi; Maria A Rocca
Journal:  J Neurol       Date:  2022-03-01       Impact factor: 4.849

6.  Consensus Paper: Ataxic Gait.

Authors:  Pierre Cabaraux; Sunil K Agrawal; Huaying Cai; Rocco Salvatore Calabro; Carlo Casali; Loic Damm; Sarah Doss; Christophe Habas; Anja K E Horn; Winfried Ilg; Elan D Louis; Hiroshi Mitoma; Vito Monaco; Maria Petracca; Alberto Ranavolo; Ashwini K Rao; Serena Ruggieri; Tommaso Schirinzi; Mariano Serrao; Susanna Summa; Michael Strupp; Olivia Surgent; Matthis Synofzik; Shuai Tao; Hiroo Terasi; Diego Torres-Russotto; Brittany Travers; Jaimie A Roper; Mario Manto
Journal:  Cerebellum       Date:  2022-04-12       Impact factor: 3.847

Review 7.  Epidemiology and treatment of multiple sclerosis in elderly populations.

Authors:  Caila B Vaughn; Dejan Jakimovski; Katelyn S Kavak; Murali Ramanathan; Ralph H B Benedict; Robert Zivadinov; Bianca Weinstock-Guttman
Journal:  Nat Rev Neurol       Date:  2019-06       Impact factor: 42.937

8.  Occulomotor Neural Integrator Dysfunction in Multiple Sclerosis: Insights From Neuroimaging.

Authors:  Peter Bede; Eoin Finegan; Rangariroyashe H Chipika; Stacey Li Hi Shing; Jeffrey Lambe; James Meaney; Janice Redmond
Journal:  Front Neurol       Date:  2018-08-23       Impact factor: 4.003

Review 9.  Brain imaging of locomotion in neurological conditions.

Authors:  Gilles Allali; Helena M Blumen; Hervé Devanne; Elvira Pirondini; Arnaud Delval; Dimitri Van De Ville
Journal:  Neurophysiol Clin       Date:  2018-10-25       Impact factor: 3.734

10.  Pediatric Multiple Sclerosis Severity Score in a large US cohort.

Authors:  Jonathan D Santoro; Michael Waltz; Greg Aaen; Anita Belman; Leslie Benson; Mark Gorman; Manu S Goyal; Jennifer S Graves; Yolanda Harris; Lauren Krupp; Timothy Lotze; Soe Mar; Manikum Moodley; Jayne Ness; Mary Rensel; Moses Rodriguez; Teri Schreiner; Jan-Mendelt Tillema; Emmanuelle Waubant; Bianca Weinstock-Guttman; Brigitte F Hurtubise; Shelly Roalstad; John Rose; T Charles Casper; Tanuja Chitnis
Journal:  Neurology       Date:  2020-07-20       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.